Fundz

Who to call at Shuttle Pharmaceuticals Holdings, Inc., and when

Fundz watches for the moments Shuttle Pharmaceuticals Holdings, Inc. starts buying, and tells you who to reach.

  • An alert the day Shuttle Pharmaceuticals Holdings, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Shuttle Pharmaceuticals Holdings, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Shuttle Pharmaceuticals Holdings, Inc.. With Fundz connected, it knows.

See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2
Back to SEC Filings
Executive ChangeItem 5.02 · 8-KMEDIUM RiskNegative

Shuttle Pharmaceuticals Holdings, Inc.

A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.

Filed: Nov 28, 2025Gaithersburg, MarylandCIK: 0001757499Health Care
View on SEC.gov

2 executive changes at Shuttle Pharmaceuticals Holdings in the last 90 days. Clusters like this usually mean more senior seats open over the next few months.

See every company with multiple executive changes →

AI Executive Summary

AI-powered analysis of 8-K filing content

Shuttle Pharmaceuticals' CFO Timothy Lorber resigned effective November 21, 2025, and Interim CEO Christopher Cooper assumed the CFO and principal financial officer role while the company searches for a permanent replacement. The separation agreement includes transition payments and accelerated vesting of 39,854 RSUs, which signals a managed handoff rather than a disruptive exit.

Key Takeaways

CFO Timothy Lorber resigned effective immediately on November 21, 2025, and his separation agreement requires part-time transition services at 50% of base salary through December 4, 2025.

Interim CEO Christopher Cooper took over the CFO and principal financial officer role effective November 21, 2025, and will hold it until the company names a permanent CFO.

3 more takeaways

Related Filings (12)

12 more filings from Shuttle Pharmaceuticals Holdings, Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateNov 28, 2025
Item5.02
CategoryExecutive Change
CIK0001757499
Accession #0001493152-25-025430
Risk LevelMEDIUM
SentimentNegative
Signalrisk
Topics
executive departureleadership transitionmaterial agreement

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings

Shuttle Pharmaceuticals Holdings, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

4 screens from a live account. No signup.